Merck Faces Product Liability Trial Over $8.9B Gardasil Sales Peak
Merck's human papillomavirus vaccine Gardasil recorded peak global sales of $8.9 billion before the company was hit with a new product liability trial over alleged adverse effects. The litigation could expose Merck to significant damages and pressure on future revenue projections for its flagship vaccine.
1. Gardasil Liability Trial
Merck is defending product liability claims relating to its Gardasil HPV vaccine, which reached $8.9 billion in global sales at its peak. Plaintiffs allege the vaccine caused serious adverse health events, seeking compensatory and punitive damages. The trial outcome could force Merck to increase legal reserves, revise guidance and dent investor confidence.
Related News
BULL
Webull Users’ Semiconductor Holdings Reach 9% While Options Volume Rises 10%
BULL•
ADI
Analog Devices Q2 Industrial Segment Grows Over 40%, Bets on Empower Acquisition
ADI•
RXO
RXO Sees 16.5% Q1 Spot Rate Surge, Projects Flat Q2 Profits
RXO•
STLA
Stellantis Signs Jaguar Land Rover MOU and 51/49 JV for US, Europe EVs
STLA•
LRCX
Lam Research Price Target Raised to $340 as WFE Forecasts Rise 21.4%
LRCX•
Sources
BF